Reversal agent for antiplatelet effect of P2Y12 inhibitor receives FDA Breakthrough Therapy designation
It was announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for PB2452, a reversal agent for platelet inhibition by the P2Y12 inhibitor ticagrelor. This was supported by results of a phase 1 trial, demonstrating rapid and sustained reversal of ticagrelor-induced platelet inhibition with PB2452.
Breakthrough Therapy designation is designed to expedite the development and review of promising new drugs for serious or life-threatening conditions, when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
PB2452 is a novel, recombinant, human monoclonal antibody developed to reverse the antiplatelet effect of ticagrelor in patients with major bleeding and in urgent surgery situations. A phase I trial demonstrated that PB2452 can potentially provide life-saving therapeutic benefit by mitigating concerns regarding the bleeding risk associated with antiplatelet drugs. There are currently no approved reversal agents for antiplatelet drugs.
Share this page with your colleagues and friends: